Tetanus toxoid T-cell epitope presented on Major Histocompatibility Complex (TT-epitope-MHC)

Tetanus toxoid (TT) is the formaldehyde-inactivated derivative of the tetanus toxin produced by Clostridium tetani (UniProt: P04958). When administered, TT is processed by antigen-presenting cells into peptide fragments, which are then loaded onto Major Histocompatibility Complex (MHC) molecules, primarily Class II, for presentation to CD4+ T cells (Demotz et al., 1989; PubMed: 2524057). These T-cell epitopes, such as the well-characterized P2 and P30 sequences, are considered universal because they can bind to a wide range of human leukocyte antigen (HLA) alleles (Panina-Bordignon et al., 1989; PubMed: 2470161). Because of widespread vaccination, most individuals possess a robust pool of memory T cells specific to these TT-epitope-MHC complexes. In drug development, these complexes are targeted to provide bystander help, where the pre-existing immune response to tetanus is leveraged to enhance the immunogenicity of conjugated polysaccharides or tumor-associated antigens (Valmori et al., 1992; PubMed: 1371744). This mechanism is fundamental to the efficacy of many conjugate vaccines and is currently being explored in neoantigen-based cancer therapies to overcome immune tolerance.

Other names

Tetanus toxoid-derived T-cell epitopesTT-epitopesMHC-restricted tetanus toxoid peptidesP2 and P30 universal epitopesTetanus toxoid helper epitopes

The mechanism involves the presentation of tetanus toxoid-derived peptides by MHC Class II molecules to memory CD4+ T cells, which then provide essential signals (such as CD40L and cytokines) to B cells or other immune effectors, thereby amplifying the immune response against the linked antigen.